Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Seres.

Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The common stock described are being offered by Seres pursuant to a shelf registration statement on Form S-3 (No. 333-216735), including a prospectus, which was declared effective by the Securities and Exchange Commission (“SEC”) on March 24, 2017. A preliminary prospectus supplement to the prospectus describing the terms of the offering was filed with the SEC on June 5, 2019, and a final prospectus supplement will be filed with the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting: Goldman Sachs & Co. LLC by mail at Prospectus Department, 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at [phone], by fax at [phone], or by email at [e-mail] or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by telephone at [phone].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005892/en/